CGEM
NASDAQCullinan Therapeutics Inc.
News · 26 weeks46+350%
2026-03-012026-08-23
Mix2490d
- Insider10(42%)
- Other7(29%)
- SEC Filings6(25%)
- Earnings1(4%)
Latest news
25 items- PRZipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung CancerPresentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposium 2 at the International Association for the Study of Lung Cancer's (IASLC) 2026 World Conference on Lung Cancer (WCLC), to be held September 12-15, 2026, in Seoul, South Korea. REZILIENT3 evaluates zipalertinib plus chemotherapy versus chemotherapy alone in
- INSIDERChief Scientific Officer Michaelson Jennifer exercised 30,000 shares at a strike of $4.30 and sold $607,800 worth of shares (30,000 units at $20.26) as part of a pre-agreed trading plan (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Cullinan Therapeutics Inc.SCHEDULE 13G - Cullinan Therapeutics, Inc. (0001789972) (Subject)
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRZipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung CancerTaiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, met its primary endpoint of progression-free survival (PFS) at a planned interim analysis. In this analysis, the study demonstrated a statistically significant and clinically meaningful
- SECSEC Form SCHEDULE 13G filed by Cullinan Therapeutics Inc.SCHEDULE 13G - Cullinan Therapeutics, Inc. (0001789972) (Subject)
- SECSEC Form 10-Q filed by Cullinan Therapeutics Inc.10-Q - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsCLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase 1/2 basket study in autoimmune cytopenias to begin early 2027 CLN-049 (FLT3 TCE) potentially registrational Phase 2 study in R/R AML to begin in Q3 2026 Cash and investments of $356 million as of June 30, 2026; runway into 2029 CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer,
- PRCullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AMLCAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced positive feedback from the U.S. Food and Drug Administration (FDA) following an End-of-Phase 1 (EOP1) meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia (AML). The EOP1 meeting focused on the planned Phase 2 development strategy for CLN-049. Based on discussions with the FDA, Cullinan will initiate a potentially registrational Phase 2 study of CLN-049 in pati
- INSIDERChief Scientific Officer Michaelson Jennifer exercised 4,000 shares at a strike of $4.30 and sold $142,560 worth of shares (8,000 units at $17.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 162,844 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERChief Legal Officer Sumer Jacquelyn L was granted 2,470 shares, increasing direct ownership by 2% to 130,559 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERChief Financial Officer Fenton Mary Kay was granted 1,541 shares, increasing direct ownership by 1% to 127,921 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERSEC Form 4 filed by Director Rosenberg Anthony4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERSEC Form 4 filed by Director Allen Andrew R4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERSEC Form 4 filed by Director Webster Stephen W4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERSEC Form 4 filed by Director Meek David D.4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERSEC Form 4 filed by Director Doyle Mittie4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERSEC Form 4 filed by Director Thistle Mary4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune DiseasesCLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-refractory patient, with a favorable safety profile Initial velinotamig (BCMA TCE) data show promising clinical activity, including complete renal responses in lupus nephritis, supporting potential in plasma cell–driven autoimmune diseases Complementary T cell engager portfolio unlocks broad commercial opportunity across B cell–driven and autoantibody-mediated diseases Management to host Immunology D
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 CongressClinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan's Immunology Day on June 10 CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential firs
- PRCullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell EngagerNew and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies Initial data from the first multi-dose cohort of RA study to be presented Initial data from the first multi-dose cohort of velinotamig study also to be shared Leading key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser to share clinical perspectives The Company will host the in-person event for analysts and institutional investors on Wednesday, June 10, starting at 8:30 a.m. ET in New York City CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biop
CGEM FAQ
7 questionsWhat does Cullinan Therapeutics Inc. do?
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the...Where does CGEM stock trade?
Cullinan Therapeutics Inc. (CGEM) is listed on NASDAQ.What sector and industry is CGEM in?
Cullinan Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Cullinan Therapeutics Inc. go public?
Cullinan Therapeutics Inc. (CGEM) completed its IPO in 2021.What are analysts saying about CGEM?
Cullinan Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $3300.00 price target on 2026-02-17. Recent price targets range from $2200.00 to $4000.00.What companies are similar to CGEM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare CGEM side-by-side with any of them on Quantisnow.How can I track CGEM on Quantisnow?
Quantisnow aggregates Cullinan Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGEM to receive live email and push alerts on every new disclosure.